The Vanderbilt Atrial Fibrillation Ablation Registry (VAFAR)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02404415 |
Recruitment Status :
Recruiting
First Posted : March 31, 2015
Last Update Posted : March 5, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Atrial Fibrillation |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 3000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 10 Years |
Official Title: | The Vanderbilt Atrial Fibrillation Ablation Registry |
Study Start Date : | October 2011 |
Estimated Primary Completion Date : | October 2026 |
Estimated Study Completion Date : | October 2026 |
- Atrial fibrillation recurrence [ Time Frame: 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion criteria:
- Age >18 years
- Able to give written, informed consent
- Scheduled for an ablation procedure to treat atrial fibrillation
Exclusion criteria:
1. None
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02404415
Contact: Moore B Shoemaker, MD, MSCI | 615 322 ext 2318 | ||
Contact: Diane M Crawford, RN | 615-936-6069 | Diane.m.crawford@vanderbilt.edu |
United States, Tennessee | |
Vanderbilt University Medical Center | Recruiting |
Nashville, Tennessee, United States, 37232 | |
Contact: Diane M Crawford, RN 615-936-6069 Diane.m.crawford@vumc.org | |
Contact: Moore B Shoemaker, MD, MSCI 615 322-2318 moore.b.shoemaker@vumc.org | |
Principal Investigator: Moore B Shoemaker, MD, MSCI | |
Sub-Investigator: Christopher R Ellis, MD | |
Sub-Investigator: Pablo Saavedra, MD | |
Sub-Investigator: Arvindh N Kanagasundram, MD | |
Sub-Investigator: George Crossley, MD | |
Sub-Investigator: Sharon Shen, MD | |
Sub-Investigator: Juan Carlos Estrada, MD | |
Sub-Investigator: Jay Montgomery, MD |
Principal Investigator: | Moore B Shoemaker, MD, MSCI | Vanderbilt University |
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | M. Benjamin Shoemaker, Clinical Instructor, Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT02404415 |
Other Study ID Numbers: |
110881 |
First Posted: | March 31, 2015 Key Record Dates |
Last Update Posted: | March 5, 2024 |
Last Verified: | March 2024 |
catheter ablation genomics |
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |